Panelists discuss how to approach patient education after progression on an ALK inhibitor, address real-world challenges during therapy transitions, and determine best options for patients progressing on lorlatinib.
Patient Education and Transition Between Therapies
Key Themes:
Notable Insights:
BMI Screening Overlooks Excess Adiposity in Children Without Obesity
September 8th 2025While body mass index (BMI) accurately identified excess adiposity in nearly all children and adolescents with obesity, it failed to detect many of those without obesity who still had excess body fat.
Read More
Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing
September 4th 2025Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).
Read More